Hypoxia Inducible Factors' Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches.
HIFs
high-grade gliomas
hypoxia
pediatric
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
04
03
2020
revised:
04
04
2020
accepted:
07
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
The brain tumor microenvironment has recently become a major challenge in all pediatric cancers, but especially in brain tumors like high-grade gliomas. Hypoxia is one of the extrinsic tumor features that interacts with tumor cells, but also with the blood-brain barrier and all normal brain cells. It is the result of a dramatic proliferation and expansion of tumor cells that deprive the tissues of oxygen inflow. However, cancer cells, especially tumor stem cells, can endure extreme hypoxic conditions by rescheduling various genes' expression involved in cell proliferation, metabolism and angiogenesis and thus, promote tumor expansion, therapeutic resistance and metabolic adaptation. This cellular adaptation implies Hypoxia-Inducible Factors (HIF), namely HIF-1α and HIF-2α. In pediatric high-grade gliomas (pHGGs), several questions remained open on hypoxia-specific role in normal brain during gliomagenesis and pHGG progression, as well how to model it in preclinical studies and how it might be counteracted with targeted therapies. Therefore, this review aims to gather various data about this key extrinsic tumor factor in pHGGs.
Identifiants
pubmed: 32326644
pii: cancers12040979
doi: 10.3390/cancers12040979
pmc: PMC7226233
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Genet. 2014 May;46(5):457-461
pubmed: 24705252
Neuro Oncol. 2014 Jan;16(1):140-6
pubmed: 24285547
Acta Neuropathol. 2019 Apr;137(4):637-655
pubmed: 30770999
Cancer Cell. 2009 Jun 2;15(6):501-13
pubmed: 19477429
Biomolecules. 2019 Aug 03;9(8):
pubmed: 31382593
J Clin Oncol. 2018 Apr 1;36(10):951-958
pubmed: 29412784
Neurosurgery. 1998 Nov;43(5):1082-95
pubmed: 9802852
Exp Cell Res. 2017 Jul 15;356(2):116-121
pubmed: 28315322
Transl Oncol. 2012 Jun;5(3):141-54
pubmed: 22741033
Acta Neuropathol. 2016 Oct;132(4):625-34
pubmed: 27573687
Cancer Res. 2009 Oct 15;69(20):7986-93
pubmed: 19826036
J Clin Invest. 2007 Apr;117(4):862-5
pubmed: 17404612
Oxid Med Cell Longev. 2017;2017:4745252
pubmed: 28757909
Cancer Res. 2019 Aug 15;79(16):4015-4025
pubmed: 31266772
Mol Aspects Med. 2016 Feb-Mar;47-48:15-23
pubmed: 26549347
Clin Cancer Res. 2010 Jul 1;16(13):3368-77
pubmed: 20570930
Am J Blood Res. 2019 Feb 15;9(1):1-14
pubmed: 30899601
Mol Cells. 2010 May;29(5):435-42
pubmed: 20396958
Cell Stem Cell. 2010 Aug 6;7(2):150-61
pubmed: 20682444
Neuro Oncol. 2020 Jan 11;22(1):139-151
pubmed: 31398252
FEBS Lett. 2007 Jul 31;581(19):3582-91
pubmed: 17586500
J Clin Oncol. 2018 Jul 1;36(19):1963-1972
pubmed: 29746225
Neuro Oncol. 2011 Oct;13(10):1049-58
pubmed: 21784756
Int J Mol Sci. 2020 Jan 15;21(2):
pubmed: 31952211
Stem Cells. 2010 May;28(5):851-62
pubmed: 20309962
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
J Neurosurg. 2017 Feb;126(2):460-466
pubmed: 27177177
Nat Commun. 2019 Oct 4;10(1):4529
pubmed: 31586101
Life Sci Alliance. 2019 Mar 25;2(2):
pubmed: 30910807
Anticancer Res. 2014 Apr;34(4):1939-45
pubmed: 24692729
J Neurosci. 2019 Mar 13;39(11):1982-1993
pubmed: 30651332
Proteomics. 2019 Nov;19(21-22):e1800479
pubmed: 31328874
Int J Mol Sci. 2018 Sep 22;19(10):
pubmed: 30248992
J Nucl Med. 2017 Aug;58(8):1264-1269
pubmed: 28360212
Cancer Res. 2019 May 1;79(9):2111-2123
pubmed: 30877103
Neuro Oncol. 2014 Jan;16(2):280-91
pubmed: 24305704
J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39
pubmed: 16783163
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):15-22
pubmed: 30006019
Front Cell Dev Biol. 2018 Oct 10;6:132
pubmed: 30364203
Oncotarget. 2017 Dec 28;9(4):5233-5250
pubmed: 29435175
Neuro Oncol. 2005 Apr;7(2):134-53
pubmed: 15831232
J Neurooncol. 2019 Jan;141(2):253-263
pubmed: 30446898
Neurosurgery. 2010 Nov;67(5):1319-27; discussion 1327-8
pubmed: 20871424
Front Oncol. 2018 Jul 03;8:239
pubmed: 30018882
J Neurooncol. 2019 Oct;145(1):177-184
pubmed: 31522324
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31779235
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
Development. 2018 Oct 26;145(20):
pubmed: 30237244
Acta Neuropathol. 2012 Sep;124(3):439-47
pubmed: 22661320
PLoS One. 2014 Aug 01;9(8):e103835
pubmed: 25084455
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Acta Neuropathol Commun. 2018 Nov 5;6(1):117
pubmed: 30396367
Neuro Oncol. 2015 Jan;16 Suppl 10:x1-x36
pubmed: 25542864
Stem Cells. 2009 Jan;27(1):7-17
pubmed: 18832593
Cell. 2017 Aug 24;170(5):845-859.e19
pubmed: 28823557
J Neurooncol. 2019 May;143(1):79-86
pubmed: 30810873
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Brain Res. 2019 Jul 1;1714:88-98
pubmed: 30768929
Science. 2018 Apr 20;360(6386):331-335
pubmed: 29674595
Pharmacol Ther. 2016 Aug;164:152-69
pubmed: 27139518
Hypoxia (Auckl). 2015 Sep 18;3:35-43
pubmed: 27774480
Brain Pathol. 2019 Jul;29(4):469-472
pubmed: 31038238
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Handb Clin Neurol. 2018;148:785-797
pubmed: 29478614
Crit Rev Neurobiol. 1991;6(3):149-82
pubmed: 1773451
NPJ Genom Med. 2020 Mar 10;5:11
pubmed: 32194984
Oncogene. 2009 Nov 12;28(45):3949-59
pubmed: 19718046
Trends Cancer. 2016 Dec;2(12):758-770
pubmed: 28741521
Oncotarget. 2017 Mar 23;8(42):71597-71617
pubmed: 29069732